8-K filing — American Healthcare REIT, Inc. (AHR)
Filed: 2026-09-14 AccNo: 0001193125-26-389802 Size: 147 KB Item 7.01: Regulation FD Disclosure
Stocks · News reference
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Top Wall Street analysts change outlook on top stocks. For analyst rating changes, see https://www.benzinga.com/analyst-stock-ratings. INSM initiated with $192 PT.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
American Healthcare REIT Acquires 8 Class A Senior Housing Communities For Approximately $696M, Establishing A New Operating Relationship With LCB Senior Living And A Substantial Presence In Supply-constrained East Coast Markets
AHR secured a 10-community opportunity and simultaneously assigned two of the properties at their allocated basis, capturing the opportunity without compromising capital allocation disciplineThe eight communities
American Healthcare REIT Announces Brian Peay To Retire As CFO Effective September 30, 2026
American Healthcare REIT, Inc. (NYSE:AHR) (the "Company" or "AHR") today announced that Aric Chang has been appointed Chief Financial Officer, effective October 1, 2026. Chang succeeds Brian Peay, who is
American Healthcare REIT Appoints Aric Chang As CFO Effective On October 1, 2026
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company
PVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.
HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $290 Price Target